{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:00:31Z","timestamp":1790254831854,"version":"4.1.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pancreatic adenocarcinoma (PDAC) is a devastating disease with an urgent need for therapeutic innovation. Immune checkpoint inhibition has shown promise in a variety of solid tumors, but most clinical trials have failed to demonstrate clinical efficacy in PDAC. This low efficacy is partly explained by a highly immunosuppressive microenvironment, which dampens anti-tumor immunity through the recruitment or induction of immunosuppressive cells, particularly regulatory T cells (Tregs). In this context, our laboratory has developed a novel immunotherapeutic strategy aimed at inhibiting the suppressive activity of Tregs, based on a patented (EP3152234B1) monoclonal antibody (mAb) targeting galectin-9 (LGALS9).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>CD4+ conventional T cells (TCD4 or Tconv), Treg ratio, and LGALS9 expression were analyzed by immunohistochemistry (IHC) and cytometry in blood and pancreas of K-rasLSL.G12D\/+;Pdx-1-Cre (KC) and K-rasWildType (WT);Pdx1-Cre (WT) mice aged 4\u201313 months. Pancreatic intraepithelial neoplasm (PanIN) progression and grade were quantified using FIJI software and validated by pathologists. The anti-galectin-9 mAb was validated for its use in mice on isolated murine C57BL\/6 Treg by immunofluorescence staining and cytometry. Its specificity and functionality were validated in proliferation assays on rLGALS9-immunosuppressed murine Tconv and in suppression assays between murine Treg and Tconv. Finally, 2-month-old KC mice were treated with anti-LGALS9 and compared to WT mice for peripheral and infiltrating TCD4, Treg, and PanIN progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>IHC and cytometry revealed a significant increase in LGALS9 expression and Treg levels in the blood and pancreas of KC mice proportional to the stages of precancerous lesions. Although present in WT mice, LGALS9 is expressed at a basal level with low and restricted expression that increases slightly over time, while Treg cells are few in number in their circulation and even absent from the pancreas over time. Using our anti-LGALS9 mAb in mice, it is shown that (i) murine Treg express LGALS9, (ii) the mAb could target and inhibit recombinant murine LGALS9, and (iii) neutralize murine Treg suppressive activity. Finally, the anti-LGALS9 mAb in KC mice reduced (i) LGALS9 expression in pancreatic cancer cells, (ii) the Treg ratio, and (iii) the total surface area and grade of PanIN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We demonstrate for the first time that an anti-LGALS9 antibody, by specifically targeting endogenous LGALS9 tumor and exogenous LGALS9 produced by Treg, was able to limit the progression of pancreatic neoplastic lesions in mice, opening up new prospects for its use as an immunotherapeutic tool in PDAC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1267279","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T07:20:33Z","timestamp":1701328833000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice"],"prefix":"10.3389","volume":"14","author":[{"given":"Alexandre","family":"Quilbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Mustapha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Duch\u00eane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Werkmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Leteurtre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Moral\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Jonckheere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Van Seuningen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadira","family":"Delhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30088-7","article-title":"Working together to reduce the burden of pancreatic cancer","volume":"21","author":"Landman","year":"2020","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/OP.22.00328","article-title":"Pancreatic adenocarcinoma management","volume":"19","author":"Jiang","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: A Cancer J Clin"},{"key":"B9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","article-title":"Tumor immunology and tumor evolution: intertwined histories","volume":"52","author":"Galon","year":"2020","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunotherapy"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100541","article-title":"The role of immunotherapy in pancreatic cancer","volume":"29","author":"Mukherji","year":"2022","journal-title":"Curr Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Sci (New York NY)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncology: Off J Am Soc Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.415","article-title":"Investigate the efficacy of immunotherapy for treatment of pancreatic adenocarcinoma (PDAC) with mismatch repair deficiency (dMMR)","volume":"39","author":"Noor","year":"2021","journal-title":"JCO"},{"key":"B16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13014-020-01569-5","article-title":"The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database","volume":"15","author":"Amin","year":"2020","journal-title":"Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ctro.2020.06.003","article-title":"The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor","volume":"24","author":"Amin","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1186\/s12885-020-07016-8","article-title":"The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis","volume":"20","author":"Amin","year":"2020","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jamcollsurg.2019.01.016","article-title":"Impact of immunotherapy after resection of pancreatic cancer","volume":"229","author":"Tran","year":"2019","journal-title":"J Am Coll Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.53","article-title":"Pancreatic cancer: from state-of-the-art treatments to promising novel therapies","volume":"12","author":"Garrido-Laguna","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101805","article-title":"Activation of immune evasion machinery is a part of the process of Malignant transformation of human cells","volume":"39","author":"Abooali","year":"2024","journal-title":"Trans Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4314","article-title":"Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance","volume":"23","author":"Daley","year":"2017","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1237328","DOI":"10.1080\/2162402X.2016.1237328","article-title":"Immunosuppressive \u03b3\u03b4 T cells foster pancreatic carcinogenesis","volume":"5","author":"Mondrag\u00f3n","year":"2016","journal-title":"OncoImmunology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202204_28622","article-title":"Prognostic value of regulator T cells in patients with pancreatic cancer: a systematic review and meta-analysis","volume":"26","author":"Su","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940052","article-title":"Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment","volume":"13","author":"McRitchie","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"B30","volume-title":"Genetically engineered mouse models of pancreatic cancerCancer J","author":"Westphalen","year":"2012"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2015.10.014","article-title":"The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK\/AP-1, NF-\u03baB and RalB signaling pathways","volume":"1849","author":"Vasseur","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00309-X","article-title":"Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse","volume":"4","author":"Hingorani","year":"2003","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.05.020","article-title":"A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)","volume":"10","author":"Lv","year":"2023","journal-title":"Genes Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01594","article-title":"The tim-3-galectin-9 pathway and its regulatory mechanisms in human breast cancer","volume":"10","author":"Yasinska","year":"2019","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"10349","DOI":"10.1038\/s41598-017-10386-y","article-title":"The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9\/Tim-3-related changes in the tumour microenvironment","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3892\/or.2021.8056","article-title":"Galectin\u22129 suppresses the tumor growth of colon cancer","volume":"45","author":"Morishita","year":"2021","journal-title":"Vitro vivo. Oncol Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1186-7","article-title":"Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels","volume":"39","author":"Seifert","year":"2020","journal-title":"Oncogene"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1237328","article-title":"Immunosuppressive \\textbackslashtextlessb\\textbackslashtextgreater\u03b3\u03b4\\textbackslashtextless\/b\\textbackslashtextgreater T cells foster pancreatic carcinogenesis","volume":"5","author":"Mondrag\u00f3n","year":"2016","journal-title":"OncoImmunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.06.011","article-title":"Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells","volume":"41","author":"Wu","year":"2014","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.11","article-title":"miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer","volume":"34","author":"Lahdaoui","year":"2015","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cells11192952","article-title":"Role of the tumor microenvironment in regulating pancreatic cancer therapy resistance","volume":"11","author":"Deng","year":"2022","journal-title":"Cells"},{"key":"B44","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-1494","article-title":"Abstract 1494: Galectin 9 associates with PDL1 expression and promotes gastric cancer cell invasion","author":"Hill","year":"1494","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2018.1564505","article-title":"Tim-3\/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients","volume":"8","author":"Limagne","year":"2019","journal-title":"OncoImmunology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47235-z","article-title":"Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels","volume":"9","author":"Sideras","year":"2019","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clim.2008.01.006","article-title":"Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis","volume":"127","author":"Seki","year":"2008","journal-title":"Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.02.007","article-title":"Lipopolysaccharide mediates time-dependent macrophage M1\/M2 polarization through the Tim-3\/Galectin-9 signalling pathway","volume":"376","author":"Zhang","year":"2019","journal-title":"Exp Cell Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.5.2974","article-title":"Galectin-9 induces maturation of human monocyte-derived dendritic cells","volume":"175","author":"Dai","year":"2005","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700575","article-title":"Regulatory T cell\u2013mediated suppression of inflammation induced by DR3 signaling is dependent on galectin-9","volume":"199","author":"Madireddi","year":"2017","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6202","article-title":"Galectin-1 expression in activated pancreatic satellite cells promotes fibrosis in chronic pancreatitis\/pancreatic cancer via the TGF-\u03b21\/Smad pathway","volume":"39","author":"Tang","year":"2018","journal-title":"Oncol Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3013","article-title":"Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and hedgehog signaling activation","volume":"74","author":"Mart\u00ednez-Bosch","year":"2014","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0175","article-title":"Dynamics of the immune reaction to pancreatic cancer from inception to invasion","volume":"67","author":"Clark","year":"2007","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.06.062","article-title":"Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer","volume":"20","author":"Jang","year":"2017","journal-title":"Cell Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202512","article-title":"Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9","volume":"13","author":"Lhuillier","year":"2018","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302663","article-title":"T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases","volume":"192","author":"Clayton","year":"2014","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2871","article-title":"Bat3 promotes T cell responses and autoimmunity by repressing Tim-3\u2013mediated cell death and exhaustion","volume":"18","author":"Rangachari","year":"2012","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.10.079","article-title":"A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9","volume":"351","author":"van de Weyer","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15042","article-title":"TIM-3 in normal and Malignant hematopoiesis: Structure, function, and signaling pathways","volume":"112","author":"Kikushige","year":"2021","journal-title":"Cancer Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105329","article-title":"Cancer cell intrinsic TIM-3 induces glioblastoma progression","volume":"25","author":"Guo","year":"2022","journal-title":"iScience"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111719","article-title":"Tim-3 suppresses the killing effect of V\u03b39V\u03b42 T cells on colon cancer cells by reducing perforin and granzyme B expression","volume":"386","author":"Li","year":"2020","journal-title":"Exp Cell Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.601661","article-title":"The role of TIM-3 in hepatocellular carcinoma: A promising target for immunotherapy","volume":"10","author":"Ganjalikhani Hakemi","year":"2020","journal-title":"Front Oncol"},{"key":"B66","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-019-0224-6","volume-title":"TIM3 comes of age as an inhibitory receptor","author":"Wolf","year":"2020"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1177\/1721727X221092900","article-title":"Advance of T regulatory cells in tumor microenvironment remodeling and immunotherapy in pancreatic cancer","volume":"20","author":"Gao","year":"2022","journal-title":"Eur J Inflammation"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.009","article-title":"Loss of somatostatin receptor subtype 2 promotes growth of KRAS-induced pancreatic tumors in mice by activating PI3K signaling and overexpression of CXCL16","volume":"148","author":"Chalabi-Dchar","year":"2015","journal-title":"Gastroenterology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/978-88-470-2613-1_8","article-title":"CXCR2 signaling regulates KRAS(G12D) -induced autocrine growth of pancreatic cancer","volume":"7","author":"Purohit","year":"2016","journal-title":"Oncotarget"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030437","article-title":"Placental galectins in cancer: why we should pay more attention","volume":"12","author":"Fuselier","year":"2023","journal-title":"Cells"},{"key":"B71","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41573-023-00636-2","article-title":"Targeting galectin-driven regulatory circuits in cancer and fibrosis","volume":"22","author":"Mari\u00f1o","year":"2023","journal-title":"Nat Rev Drug Discovery"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145268","article-title":"Galectins as pivotal components in oncogenesis and immune exclusion in human Malignancies","volume":"14","author":"Kapetanakis","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1267279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T07:20:37Z","timestamp":1701328837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1267279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":72,"alternative-id":["10.3389\/fimmu.2023.1267279"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1267279","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"article-number":"1267279"}}